<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1018706268302959&amp;ev=PageView&amp;noscript=1">
((o
Knowledge • News • Insights
 o))
In Partnership With

Michigan 50 Companies to Watch | Genomenon

Michigan Celebrates Small Business
May 7, 2019 1:00 PM

genomenon

In a lead-up to 2019's Michigan Celebrates Small Business Gala Celebration Jeffrey Mosher spoke with several winning companies from this cycle.

Here he speaks with Mike Klein, CEO of one of Michigan 50 Companies to Watch in 2019, Genomenon, Ann Arbor, MI

To listen to the full interview please click on the embedded SoundCloud PodCast below! 

Genomenon, Ann Arbor, MI

mike-klein-bio-squareMike Klein (Shown Left) with over 25 years of developing, building and growing 4 different high tech companies, Mike raised over $50M in capital and had several successful investor exits. In fact Genomenon is the third company Mike has led to being honored by the Michigan 50 Companies to Watch category!
 
Interpretation of next-generation sequencing DNA data is frustratingly inefficient and error prone due to the time consuming, manual approach required to search and curate the rapidly growing body of medical literature for disease-related genes and variants.

Genomenon has replaced the manual search process in gene and variant interpretation with a genomic search engine and database of all the disease-gene-variant relationships found in the full text of the scientific literature. Our technology is revolutionizing the way genetic diagnoses and discoveries are made by making it easier to get rapid insight into prioritized, clinically relevant literature for both clinical decision making and research projects.

They started with all 30 million titles and abstracts from PubMed to find all the scientific articles with any genomic content. From there, they have indexed the full text of almost six million genomic articles to create Mastermind, a comprehensive genomic search engine that enables pathologists and geneticists to quickly and accurately curate disease-causing genes and variants from patients’ DNA datasets.

With a comprehensive genomic data set and deep insight into all of the genomic literature, they are able to provide some fascinating results – from accelerated gene and variant curation for clinicians – to evidence-based panel design – to biomarker candidates backed by literature citations for co-diagnostics and clinical trials.
 

Spring 2019 Michigan Future Business Index survey